Bibliografisk note

Funding Information:
The authors would like to thank the patients, their families and all investigators involved in this study. Medical writing support, including assisting authors with the development of the initial draft and incorporation of comments, was provided by R. Wright, and editorial support, including referencing, figure preparation, formatting, proofreading and submission, was provided by Ian Norton, PhD, all of Scion, London, supported by Bayer AG according to Good Publication Practice guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460). These data have been previously presented in part at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022) and the 22nd EURETINA Congress (1–4 September 2022). This work was supported by Bayer AG, who funded the ReFineDR and DeFineDR studies and combined analysis.

Funding Information:
This work was funded by Bayer AG, Wuppertal, Germany.